mars 26, 2020
Addressing the Coronavirus Impact: Emerging Markets Leaders Portfolio
mars 26, 2020
Addressing the Coronavirus Impact: Emerging Markets Leaders Portfolio
mars 26, 2020
With global markets experiencing unprecedented volatility, we offer some insight into the Emerging Markets Leaders strategy and updates on the portfolio changes. We remain focused on the high quality, long term structural growth companies that we believe will emerge from this bout of volatility and dislocation in a more dominant position.
We have remained disciplined to our investment philosophy and process throughout this unusual period of market swings that has impacted our portfolio as well. We continue to be invested in high quality companies with high return on invested capital and strong balance sheets, and continue to add / rotate capital into positions that we believe will emerge even stronger from this dislocation. Following the first round of impact (and recovery) in China, our portfolio has been impacted by Covid-19 cases spiking in our geographies of exposure. In all these cases, we believe the dislocations are due to extrapolation of near-term cash flow impacts to longer-term trajectories of cash flows (i.e. valuation impacts), or due to undue existential concerns. Alongside, currency devaluations, be it the Indian Rupee or the Brazilian Real, have further exacerbated the near-term pain.
There is, at the moment, a significant uncertainty and fear prevalent in the market about what the end result will look like. However, we have already witnessed China, South Korea, Hong Kong and Singapore taking on the virus head-on via lockdowns, strict social distancing, and international border closures. These measures combined with support from healthcare infrastructure, and natural time for healing has demonstrated a viable path to flattening the case curve, and we hope in near-future disease control, if not eradication, with or without a vaccine. It is encouraging to now see countries from Italy to UK to India taking these steps as well, recognizing the problem and the path to its management. While it will come down to eventual execution, and exact impacts will take time to be revealed, we remain confident that not only will our portfolio weather the storm, but emerge stronger from this.
It is important for investors to recognize that Covid-19 is a very unique event in the history of stock market. Never before has it happened that a number of large global economies have literally shut down simultaneously at the “flick of a switch.” Given the scale and scope of this natural disaster, it is extremely difficult to own a business which would be completely immune to the economic and stock market dislocations arising from it. We are very cognizant that going forward, Covid-19 will have a material impact on the economic and social fabric of our societies. However, our investment process and philosophy of investing into companies with high ROIC, net cash, solid balance sheets, leadership, sustainable competitive advantages, large addressable markets, excellent management, and predictable earnings growth with long future runways, becomes even more relevant.
We believe that our invested companies have strong franchise value with the expected long-term reward outweighing the recent spike in risk. We expect our investments to be well positioned for the recovery phase whenever it comes. These companies will likely emerge more dominant from this period of crisis as many of the less well-equipped competitors will face supply chain disruptions, working capital shortage and inventory adjustments – not to mention, some indebted competitors might simply disappear, or become insignificant. Note that we have seen strong evidence of a number of our companies increasing their focus on customers and vendors alike during this challenging period, supporting the whole chain despite some near-term pain – and this will create critical loyalty ahead.
Our high conviction on the multiyear growth runways of the Chinese Ecosystems has led us to increase our holdings during this time. These companies have already been a significant source of excess returns so far this year, and that should continue. We expect these leaders to strengthen their footholds on the way up, raising penetration followed by take-rates, and launching new areas of growth, spurring positive operating leverage as normalcy ensues. Online Education has performed strongly during this time, seeing increased adoption. To this end, we shifted some capital from a mixed business model company to a pure-play online education company. Being purely online, this business model is massively scalable and has inherently high ROIC. We note that these shifts towards ecosystems and online education aren’t transitory, especially in China, but more a behavioural shift.
On a slightly tepid tone, city closures meant closure of storefronts and curbs on free movement, which hit our Athleisure names badly. While near-term demand has definitely plummeted, however, China has positively surprised us in the speed of storefronts reopening (>85% from latest surveys). Managements and distributors alike have noted that spring inventory clearance is progressing well (~45-50% cleared) with little adverse discounting from last year. If China’s path is any indication of things to come, we remain optimistic for the recovery for the globe as a whole, especially if governments are tackling this head-on. Interestingly, high margin online channels actually saw more traction for our companies during this time, and being leaders in their own rights, we see evidence of market share gains.
Onto the major detractors – India and LatAm. In India, worries over Covid-19 and the subsequent closures of businesses during this time have led to worries of a systematic liquidity crunch. This coupled with the recent Yes Bank fiasco has meant that Indian Financials have taken the brunt of the sell-off. While near-term pain is inevitable, this could be a blessing in disguise, as our investment holdings are all well capitalized and efficiently run private enterprises that will likely gain market share. Our LatAm companies have given up almost all their absolute gains, and then some, in the recent sell-off, further exacerbated by the fall in oil prices. Our thesis of these companies disrupting the financial system and gaining market share remains unchanged. Penetration rates have now reached a level where there is critical mass in our view. In fact, as the situation normalizes, cash aversion and e-money adoption should accelerate. Our companies remain well-funded with strong net-cash balance sheets, and are well positioned on the way up, once markets stabilize.
We believe that the current crisis will sow the seeds for specific new investment opportunities over the next decade. Acceleration in online adoption, increasing AI, and increasing focus on healthcare, are some themes that we are currently researching in depth. We remain true to our investment philosophy, our process, and quite excited looking into the future.
There is no assurance that a portfolio will achieve its investment objective. Portfolios are subject to market risk, which is the possibility that the market values of securities owned by the portfolio will decline. Accordingly, you can lose money investing. Please be aware that this portfolio may be subject to certain additional risks. In general, equities securities’ values also fluctuate in response to activities specific to a company. Investments in foreign markets entail special risks such as currency, political, economic, market and liquidity risks. The risks of investing in emerging market countries are greater than the risks generally associated with investments in foreign developed countries. Stocks of small- and medium capitalization companies entail special risks, such as limited product lines, markets, and financial resources, and greater market volatility than securities of larger, more established companies. Derivative instruments can be illiquid, may disproportionately increase losses and may have a potentially large negative impact on the Portfolio’s performance. Illiquid securities may be more difficult to sell and value than publicly traded securities (liquidity risk). Non-diversified portfolios often invest in a more limited number of issuers. As such, changes in the financial condition or market value of a single issuer may cause greater volatility. Privately placed and restricted securities may be subject to resale restrictions as well as a lack of publicly available information, which will increase their illiquidity and could adversely affect the ability to value and sell them (liquidity risk).
Past performance is no guarantee of future results.
The views, opinions, forecasts and estimates expressed of the author or the investment team as of the date of preparation of this material and are subject to change at any time due to market, economic or other conditions. Furthermore, the views will not be updated or otherwise revised to reflect information that subsequently becomes available or circumstances existing, or changes occurring, after the date of publication. The views expressed do not reflect the opinions of all portfolio managers at Morgan Stanley Investment Management (MSIM) or the views of the firm as a whole, and may not be reflected in all the strategies and products that the Firm offers.
Forecasts and/or estimates provided herein are subject to change and may not actually come to pass. Information regarding expected market returns and market outlooks is based on the research, analysis and opinions of the authors. These conclusions are speculative in nature and are not intended to predict the future performance of any specific Morgan Stanley Investment Management product.
Certain information herein is based on data obtained from third-party sources believed to be reliable. However, we have not verified this information, and we make no representations whatsoever as to its accuracy or completeness.
This material is a general communication, which is not impartial, and all information provided has been prepared solely for informational and educational purposes and does not constitute an offer or a recommendation to buy or sell any particular security or to adopt any specific investment strategy. The information herein has not been based on a consideration of any individual investor circumstances and is not investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. To that end, investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision.
This communication is not a product of Morgan Stanley’s Research Department and should not be regarded as a research recommendation. The information contained herein has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This communication is only intended for and will be only distributed to persons resident in jurisdictions where such distribution or availability would not be contrary to local laws or regulations.
There is no guarantee that any investment strategy will work under all market conditions, and each investor should evaluate their ability to invest for the long term, especially during periods of downturn in the market. Prior to investing, investors should carefully review the strategy’s/product’s relevant offering document. There are important differences in how the strategy is carried out in each of the investment vehicles.
Ireland: Morgan Stanley Investment Management (Ireland) Limited. Registered Office: The Observatory, 7-11 Sir John Rogerson’s Quay, Dublin 2, Ireland. Registered in Ireland under company number 616662. Regulated by the Central Bank of Ireland. United Kingdom: Morgan Stanley Investment Management Limited is authorised and regulated by the Financial Conduct Authority. Registered in England. Registered No. 1981121. Registered Office: 25 Cabot Square, Canary Wharf, London E14 4QA. Dubai: Morgan Stanley Investment Management Limited (Representative Office, Unit Precinct 3-7th Floor-Unit 701 and 702, Level 7, Gate Precinct Building 3, Dubai International Financial Centre, Dubai, 506501, United Arab Emirates. Telephone: +97 (0)14 709 7158). Germany: Morgan Stanley Investment Management Limited Niederlassung Deutschland, Grosse Gallustrasse 18, 60312 Frankfurt am Main, Germany (Gattung: Zweigniederlassung (FDI) gem. § 53b KWG). Italy: Morgan Stanley Investment Management Limited, Milan Branch (Sede Secondaria di Milano) is a branch of Morgan Stanley Investment Management Limited, a company registered in the U.K., authorised and regulated by the Financial Conduct Authority (FCA), and whose registered office is at 25 Cabot Square, Canary Wharf, London, E14 4QA. Morgan Stanley Investment Management Limited Milan Branch (Sede Secondaria di Milano) with seat in Palazzo Serbelloni Corso Venezia, 16 20121 Milano, Italy, is registered in Italy with company number and VAT number 08829360968. The Netherlands: Morgan Stanley Investment Management, Rembrandt Tower, 11th Floor Amstelplein 1 1096HA, Netherlands. Telephone: 31 2-0462-1300. Morgan Stanley Investment Management is a branch office of Morgan Stanley Investment Management Limited. Morgan Stanley Investment Management Limited is authorised and regulated by the Financial Conduct Authority in the United Kingdom. Switzerland: Morgan Stanley & Co. International plc, London, Zurich BranchI Authorised and regulated by the Eidgenössische Finanzmarktaufsicht (“FINMA”). Registered with the Register of Commerce Zurich CHE-115.415.770.
Registered Office: Beethovenstrasse 33, 8002 Zurich, Switzerland, Telephone +41 (0) 44 588 1000. Facsimile: +41 (0) 44 588 1074.
Hong Kong: This document has been issued by Morgan Stanley Asia Limited for use in Hong Kong and shall only be made available to “professional investors” as defined under the Securities and Futures Ordinance of Hong Kong (Cap 571). The contents of this document have not been reviewed nor approved by any regulatory authority including the Securities and Futures Commission in Hong Kong. Accordingly, save where an exemption is available under the relevant law, this document shall not be issued, circulated, distributed, directed at, or made available to, the public in Hong Kong. Singapore: This publication should not be considered to be the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other than (i) to an institutional investor under section 304 of the Securities and Futures Act, Chapter 289 of Singapore (“SFA”); (ii) to a “relevant person” (which includes an accredited investor) pursuant to section 305 of the SFA, and such distribution is in accordance with the conditions specified in section 305 of the SFA; or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. This publication has not been reviewed by the Monetary Authority of Singapore. Australia: This publication is disseminated in Australia by Morgan Stanley Investment Management (Australia) Pty Limited ACN: 122040037, AFSL No. 314182, which accept responsibility for its contents. This publication, and any access to it, is intended only for “wholesale clients” within the meaning of the Australian Corporations Act.
Japan: For professional investors, this document is circulated or distributed for informational purposes only. For those who are not professional investors, this document is provided in relation to Morgan Stanley Investment Management (Japan) Co., Ltd. (“MSIMJ”)’s business with respect to discretionary investment management agreements (“IMA”) and investment advisory agreements (“IAA”). This is not for the purpose of a recommendation or solicitation of transactions or offers any particular financial instruments. Under an IMA, with respect to management of assets of a client, the client prescribes basic management policies in advance and commissions MSIMJ to make all investment decisions based on an analysis of the value, etc. of the securities, and MSIMJ accepts such commission. The client shall delegate to MSIMJ the authorities necessary for making investment. MSIMJ exercises the delegated authorities based on investment decisions of MSIMJ, and the client shall not make individual instructions. All investment profits and losses belong to the clients; principal is not guaranteed. Please consider the investment objectives and nature of risks before investing. As an investment advisory fee for an IAA or an IMA, the amount of assets subject to the contract multiplied by a certain rate (the upper limit is 2.20% per annum (including tax)) shall be incurred in proportion to the contract period. For some strategies, a contingency fee may be incurred in addition to the fee mentioned above. Indirect charges also may be incurred, such as brokerage commissions for incorporated securities. Since these charges and expenses are different depending on a contract and other factors, MSIMJ cannot present the rates, upper limits, etc. in advance. All clients should read the Documents Provided Prior to the Conclusion of a Contract carefully before executing an agreement. This document is disseminated in Japan by MSIMJ, Registered No. 410 (Director of Kanto Local Finance Bureau (Financial Instruments Firms)), Membership: The Japan Securities Dealers Association, the Investment Trusts Association, Japan, the Japan Investment Advisers Association and the Type II Financial Instruments Firms Association.
U.S.: A separately managed account may not be suitable for all investors. Separate accounts managed according to the Strategy include a number of securities and will not necessarily track the performance of any index. Please consider the investment objectives, risks and fees of the Strategy carefully before investing. A minimum asset level is required. For important information about the investment manager, please refer to Form ADV Part 2.
Please consider the investment objective, risks, charges and expenses of the fund carefully before investing. The prospectus contains this and other information about the fund. To obtain a prospectus, download one at morganstanley.com/im or call 1- 800-548-7786. Please read the prospectus carefully before investing.
Morgan Stanley Distribution, Inc. serves as the distributor for Morgan Stanley funds.
NOT FDIC INSURED | OFFER NO BANK GUARANTEE | MAY LOSE VALUE | NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY | NOT A DEPOSIT
EMEA: This communication has been issued by Morgan Stanley Investment Management Limited (“MSIM”). Authorised and regulated by the Financial Conduct Authority. Registered in England No. 1981121. Registered Office: 25 Cabot Square, Canary Wharf, London E14 4QA.
The indexes are unmanaged and do not include any expenses, fees or sales charges. It is not possible to invest directly in an index. Any index referred to herein is the intellectual property (including registered trademarks) of the applicable licensor. Any product based on an index is in no way sponsored, endorsed, sold or promoted by the applicable licensor and it shall not have any liability with respect thereto.
MSIM has not authorised financial intermediaries to use and to distribute this document, unless such use and distribution is made in accordance with applicable law and regulation. Additionally, financial intermediaries are required to satisfy themselves that the information in this document is suitable for any person to whom they provide this document in view of that person’s circumstances and purpose. MSIM shall not be liable for, and accepts no liability for, the use or misuse of this document by any such financial intermediary.
This document may be translated into other languages. Where such a translation is made this English version remains definitive. If there are any discrepancies between the English version and any version of this document in another language, the English version shall prevail.
The whole or any part of this work may not be reproduced, copied or transmitted or any of its contents disclosed to third parties without MSIM’s express written consent.
Morgan Stanley Investment Management is the asset management division of Morgan Stanley.
All information contained herein is proprietary and is protected under copyright law.